Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.

Kwok, Marwan; Agathanggelou, Angelo; Davies, Nicholas; Stankovic, Tatjana

Kwok, Marwan; Agathanggelou, Angelo; Davies, Nicholas; Stankovic, Tatjana.

Afiliação

Kwok M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.
Agathanggelou A; Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2SY, UK.
Davies N; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.
Stankovic T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.

Cancers (Basel) ; 13(18)2021 Sep 18.

Article em En | MEDLINE | ID: mdl-34572908

Palavras-chave

ATM; ATR; CDK; DNA-PK; MDM2; PARP; USP7; immunity; p53; synthetic lethality

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google